loading page

Idiopathic Pulmonary Fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension
  • +9
  • Dalia Dhia Hadi,
  • Mohammed Dheyaa Marsool Marsool,
  • Ali Dheyaa Marsool Marsool,
  • Neel Vora,
  • Sajjad Ghanim Al-Badri,
  • Nabeel Hamzah Kadhim Al-Fatlawi,
  • Ameer Fadhil Abbas Al Wssawi,
  • Abdullah Muataz Taha Al-Ibraheem,
  • Khadija Ali Hamza,
  • Priyadarshi Prajjwal,
  • Mohammed Abdul Mateen,
  • Omniat Amir
Dalia Dhia Hadi
University of Baghdad Nahda Cross Road Campus Al-Kindy College of Medicine
Author Profile
Mohammed Dheyaa Marsool Marsool
University of Baghdad Nahda Cross Road Campus Al-Kindy College of Medicine
Author Profile
Ali Dheyaa Marsool Marsool
University of Baghdad Nahda Cross Road Campus Al-Kindy College of Medicine
Author Profile
Neel Vora
BJ Medical College
Author Profile
Sajjad Ghanim Al-Badri
University of Baghdad Bab al-Moadham Campus College of Medicine
Author Profile
Nabeel Hamzah Kadhim Al-Fatlawi
University of Baghdad Bab al-Moadham Campus College of Medicine
Author Profile
Ameer Fadhil Abbas Al Wssawi
University of Al-Qadisiyah
Author Profile
Abdullah Muataz Taha Al-Ibraheem
University of Baghdad Nahda Cross Road Campus Al-Kindy College of Medicine
Author Profile
Khadija Ali Hamza
University of Baghdad Nahda Cross Road Campus Al-Kindy College of Medicine
Author Profile
Priyadarshi Prajjwal
Bharati Vidyapeeth University
Author Profile
Mohammed Abdul Mateen
Shadan Hospital and Institute of Medical Sciences
Author Profile
Omniat Amir
Al Manhal University Academy of Science

Corresponding Author:[email protected]

Author Profile

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unclear etiology. Clinical manifestations include dyspnea and nonproductive cough. Lung transplantation is the only cure, while Pirfenidone and Nintedanib are FDA-approved drugs for slowing disease progression. However, Saracatinib shows greater efficacy. This literature review assesses the safety and efficacy of IPF treatments, focusing on Pirfenidone and Nintedanib, which preserve lung function and reduce fibrosis and inflammation. We also evaluate emerging treatments such as saracatinib, pamrevlumab, pentraxin-2, BI 1015550, ziritaxestat, PBI-4050, bexotegrast, BMS-986020, TD 139, dasatinib, quercetin, and etanercept. Additional research is needed to explore the therapeutic potential and address gaps in IPF management, including exacerbation and associated pulmonary hypertension (PH). Immunosuppressive agents are used to manage IPF exacerbations, while PH is a recognized comorbidity. Clinical trials, PULSAR and SPECTRA, investigate Sotatercept as a potential PH treatment for IPF patients, showing promising results.
13 Jul 2023Submitted to Immunity, Inflammation and Disease
17 Jul 2023Submission Checks Completed
17 Jul 2023Assigned to Editor
21 Jul 2023Review(s) Completed, Editorial Evaluation Pending
22 Jul 2023Reviewer(s) Assigned
20 Sep 2023Editorial Decision: Revise Minor
01 Oct 20231st Revision Received
26 Oct 2023Review(s) Completed, Editorial Evaluation Pending
27 Oct 2023Editorial Decision: Accept